Glenmark Pharmaceuticals
750 Corporate Drive
Mahwah
NJ
07430
United States
Tel: 201-684-8000
Website: https://glenmarkpharma-us.com/
115 articles about Glenmark Pharmaceuticals
-
Harbour BioMed and Glenmark Pharmaceuticals Sign Agreement for Greater China to Develop GBR 1302, a First-in-Class Bispecific Antibody for Treatment of HER2-Positive Cancers
8/7/2018
Exclusive license agreement potentially worth more than $120 million in addition to royalties
-
Glenmark Pharmaceuticals Announces FDA Acceptance of the Company's First New Drug Application for Ryaltris™ for Patients with Seasonal Allergic Rhinitis
8/7/2018
The Prescription Drug User Fee Act (PDUFA) target action date for completion of the FDA review is March 21, 2019
-
Glenmark Pharmaceuticals and Harbour BioMed Sign Agreement for Greater China to Develop GBR 1302, a First-in-Class Bispecific Antibody for Treatment of HER2-Positive Cancers
8/6/2018
Exclusive license agreement potentially worth more than $120 million in addition to royalties
-
Glenmark Pharmaceuticals Announces Encouraging Phase 1 Results Supporting Biosimilarity Criteria for GBR 310 Compared to the Reference Product Omalizumab
7/25/2018
Glenmark is seeking use of GBR 310 for the same indications as the reference biologic for the treatment of allergic asthma and chronic idiopathic urticaria (CIU)
-
The US FDA Approves First Supplemental Abbreviated New Drug Application (sANDA) for Glenmark Pharmaceuticals' Manufacturing Facility in Monroe, North Carolina
6/18/2018
Glenmark Pharmaceuticals, a global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) provided its first supplemental Abbreviated New Drug Application (sANDA) approval.
-
Glenmark Pharmaceuticals Announces Poster Presentations on GBR 1302 and GBR 1342, HER2xCD3 and CD38xCD3 Bispecific Antibodies, at the 2018 ASCO Annual Meeting
5/25/2018
Glenmark Pharmaceuticals, a global pharmaceutical company, today announced the presentation of data from two assets in its immuno-oncology portfolio at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO).
-
Glenmark Pharmaceuticals Announces the Company's First New Drug Application for Ryaltris™ for Patients with Seasonal Allergic Rhinitis
5/21/2018
Glenmark Pharmaceuticals, a global pharmaceutical company, today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food & Drug
-
Glenmark Pharmaceuticals Announces Oral Presentation of New Data on GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody, at the International Investigative Dermatology Meeting
5/17/2018
Glenmark Pharmaceuticals, a global pharmaceutical company, today announced data from a Phase 2a, proof-of-concept study of GBR 830, an investigational, anti-OX40 monoclonal antibody being studied for the treatment of moderate-to-severe atopic dermatitis (AD), that were presented at the International Investigative Dermatology Meeting (IID) in Orlando, Florida
-
Glenmark Pharmaceuticals Announces Initiation of a Phase 2b Trial of GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis
4/16/2018
Glenmark Pharmaceuticals, a global pharmaceutical company, today announced the initiation of a Phase 2b clinical trial of GBR 830, a novel, investigational treatment for moderate-to-severe atopic dermatitis.
-
If a brand name drug loses patent protection, that often marks the date when companies can begin marketing generic versions of the drug. However, this has grown more complicated with the approvals of biosimilars.
-
Glenmark Pharmaceutical S.A. to Invest in New Translational Research Group at Biopôle Lausanne-Epalinges
3/6/2018
The new discovery group will enhance current capabilities in translational research
-
Glenmark Pharmaceuticals Presents New Data on Ryaltris™, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis at the AAAAI/WAO Joint Congress
3/5/2018
Glenmark Pharmaceuticals announced poster presentations of data from three clinical studies of Ryaltris™, an investigational fixed-dose combination nasal spray for seasonal allergic rhinitis (SAR), at the AAAAI/WAO Joint Congress in Orlando, Florida.
-
Glenmark Pharmaceuticals Enters Exclusive Collaboration Agreement with SCD Pharmaceuticals
2/22/2018
Glenmark Pharmaceuticals, a global pharmaceutical company, today announced it has entered into an exclusive agreement with Sam Chun Dang Pharm. Co. Ltd. (SCD), to develop, manufacture and market a portfolio of ophthalmic products in the U.S. and Canada.
-
Glenmark Pharma Presents New Data on GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting
2/16/2018
The GBR 830 Phase 2a study was a double-blind, placebo-controlled study in adults with moderate-to-severe atopic dermatitis that evaluated the safety, biological and clinical activity, and pharmacokinetics of GBR 830.
-
Glenmark Pharma Presents Preliminary Biomarker Data on GBR 1302, a HER2xCD3 Bispecific Monoclonal Antibody, at the ASCO-SITC Clinical Immuno-Oncology Symposium
1/25/2018
Glenmark Pharma today announced a presentation of preliminary biomarker findings from a Phase 1 study of GBR 1302.
-
Ligand Enters into Worldwide OmniAb Platform License Agreement with Glenmark Pharmaceuticals
1/11/2018
Under the license, Glenmark will be able to use the full OmniAb platform including OmniChicken, OmniRat, OmniMouse and OmniFlic to discover fully human mono- and multispecific antibodies.
-
Glenmark Pharma Announces Top-Line Results From a Phase III Safety Study Evaluating Ryaltris in Patients with Perennial Allergic Rhinitis
12/13/2017
Glenmark plans to submit the company's first NDA to the FDA for Ryaltris for the treatment of patients with SAR in the first quarter of 2018.
-
Glenmark Pharmaceuticals Announces Dosing of First Patient With Investigational Immuno-Oncology Agent GBR 1342
12/7/2017
This first-in-human, open-label study's primary objective is to assess the safety and tolerability of increasing doses of GBR 1342 in multiple myeloma patients until a maximum tolerated dose is reached.
-
Jaguar Subsidiary Napo Pharmaceuticals, Inc. And Glenmark Pharma Sign Agreement Returning Key Rights In 141 Countries To Napo, Solidifying Jaguar’s Global Commercial Control Of Mytesi (Crofelemer), Jaguar’s FDA-Approved Human Drug
9/25/2017
-
Glenmark Pharma Reports Positive Data In A Phase IIa Study Of GBR 830 For The Treatment Of Patients With Atopic Dermatitis
7/31/2017